Humana (HUM) Price Target Increased to $271.00 by Analysts at JPMorgan Chase & Co.

Humana (NYSE:HUM) had its target price increased by equities researchers at JPMorgan Chase & Co. from $253.00 to $271.00 in a research note issued to investors on Monday. The brokerage presently has a “neutral” rating on the insurance provider’s stock. JPMorgan Chase & Co.’s price target would indicate a potential upside of 1.48% from the stock’s previous close.

A number of other analysts have also issued reports on HUM. Cantor Fitzgerald reissued a “hold” rating and issued a $250.00 price target on shares of Humana in a research note on Wednesday, February 7th. Deutsche Bank raised their price target on Humana from $259.00 to $270.00 and gave the stock a “hold” rating in a research note on Friday. Leerink Swann raised their price target on Humana from $280.00 to $300.00 and gave the stock an “outperform” rating in a research note on Thursday. Credit Suisse Group raised Humana from a “neutral” rating to an “outperform” rating and decreased their price target for the stock from $264.90 to $246.00 in a research note on Thursday. Finally, Oppenheimer raised their price target on Humana from $275.00 to $305.00 and gave the stock an “outperform” rating in a research note on Thursday. Seven analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $270.47.

Shares of Humana (NYSE HUM) traded up $1.73 during trading hours on Monday, reaching $267.05. The company’s stock had a trading volume of 1,009,846 shares, compared to its average volume of 1,234,493. The company has a current ratio of 1.85, a quick ratio of 1.61 and a debt-to-equity ratio of 0.48. Humana has a 12-month low of $203.36 and a 12-month high of $293.35. The firm has a market cap of $36,528.92, a price-to-earnings ratio of 16.01, a price-to-earnings-growth ratio of 1.44 and a beta of 0.93.

Humana (NYSE:HUM) last issued its quarterly earnings results on Wednesday, February 7th. The insurance provider reported $2.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.00 by $0.06. Humana had a return on equity of 16.13% and a net margin of 4.55%. The firm had revenue of $13.19 billion for the quarter, compared to analyst estimates of $13.14 billion. During the same period last year, the company earned $2.34 EPS. The firm’s quarterly revenue was up 2.4% on a year-over-year basis. equities analysts predict that Humana will post 13.85 earnings per share for the current year.

Humana announced that its Board of Directors has approved a stock repurchase plan on Thursday, December 14th that authorizes the company to buyback $3.00 billion in outstanding shares. This buyback authorization authorizes the insurance provider to purchase shares of its stock through open market purchases. Stock buyback plans are generally an indication that the company’s board believes its stock is undervalued.

In related news, SVP Jody L. Bilney sold 7,054 shares of the firm’s stock in a transaction dated Monday, December 18th. The stock was sold at an average price of $247.89, for a total transaction of $1,748,616.06. Following the sale, the senior vice president now directly owns 11,704 shares in the company, valued at approximately $2,901,304.56. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, VP Timothy S. Huval sold 1,382 shares of the firm’s stock in a transaction dated Tuesday, December 19th. The shares were sold at an average price of $246.04, for a total value of $340,027.28. Following the sale, the vice president now owns 11,557 shares in the company, valued at $2,843,484.28. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 10,115 shares of company stock worth $2,501,627. Company insiders own 0.80% of the company’s stock.

Several large investors have recently made changes to their positions in HUM. Janus Henderson Group PLC raised its holdings in shares of Humana by 74.1% during the 3rd quarter. Janus Henderson Group PLC now owns 2,729,248 shares of the insurance provider’s stock valued at $664,921,000 after buying an additional 1,161,661 shares during the period. Koch Industries Inc. purchased a new stake in Humana during the 2nd quarter worth approximately $404,000. APG Asset Management N.V. increased its holdings in Humana by 60.3% during the 4th quarter. APG Asset Management N.V. now owns 729,519 shares of the insurance provider’s stock worth $150,709,000 after purchasing an additional 274,435 shares during the last quarter. Bank of Montreal Can increased its holdings in Humana by 118.3% during the 4th quarter. Bank of Montreal Can now owns 501,379 shares of the insurance provider’s stock worth $124,378,000 after purchasing an additional 271,701 shares during the last quarter. Finally, Old Mutual Global Investors UK Ltd. increased its holdings in Humana by 127.4% during the 3rd quarter. Old Mutual Global Investors UK Ltd. now owns 441,325 shares of the insurance provider’s stock worth $107,520,000 after purchasing an additional 247,237 shares during the last quarter. Institutional investors and hedge funds own 94.13% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This article was reported by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another domain, it was copied illegally and reposted in violation of international copyright and trademark law. The correct version of this article can be accessed at https://www.americanbankingnews.com/2018/02/12/humana-hum-price-target-increased-to-271-00-by-analysts-at-jpmorgan-chase-co.html.

Humana Company Profile

Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.

Analyst Recommendations for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply